Best Buy Announces Regular Quarterly Cash Dividend

Best Buy Announces Regular Quarterly Cash Dividend

MINNEAPOLIS–(BUSINESS WIRE)–
The Board of Directors of Best Buy Co., Inc. (NYSE:BBY) has authorized the payment of a regular quarterly cash dividend of $0.55 per common share. The quarterly dividend is payable on January 5, 2021, to shareholders of record as of the close of business on December 15, 2020. The company had 258,931,526 shares of common stock issued and outstanding as of October 31, 2020.

Investor Contact:

Mollie O’Brien

[email protected]

Media Contact:

Carly Charlson

[email protected]

KEYWORDS: United States North America Minnesota

INDUSTRY KEYWORDS: Home Goods Office Products Other Retail Specialty Consumer Electronics Technology Online Retail Retail

MEDIA:

Logo
Logo

Secure Technology Alliance Announces 2020 Honor Roll, Recognizes Members for Outstanding Contributions

PRINCETON JUNCTION, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) — The Secure Technology Alliance announced its 2020 Honor Roll members today, recognizing the top individual and member company contributors to Alliance activities and projects this year.

“We are grateful to each of our members for the time and effort they put into advancing the Secure Technology Alliance’s mission,” said Randy Vanderhoof, executive director of the Secure Technology Alliance. “Our annual honor roll helps us to recognize those who show outstanding leadership and dedication to the projects and resources we’ve produced in the last year. The great drive we have seen from all our members this year is indicative of what we can expect for 2021. Thank you to all of those who have committed valuable time to our work.”

Industry Council Recognition

The Secure Technology Alliance’s 2020 Honor Roll recognizes individual members and top contributors in the Alliance industry councils – Access Control, Identity, Payments, and Transportation – whose contributions in the past year assisted the Alliance in fulfilling its mission.

The contributions made by the member-driven councils included publishing education and outreach material for different markets, hosting webinars and workshops, developing industry positions on key government and private initiatives, and establishing relationships with related industry groups. The results of the councils’ work are viewed as authoritative educational material for both the U.S. and international secure technology markets and help drive secure technology implementations in the U.S.

The 2020 Honor Roll included 60 industry leaders and was compiled based on council leadership, project leadership, and project participation from 2019 to 2020. The top contributors on the honor roll for each industry council are:

  • Access Control Council. Chair Lars Suneborn, ID Technology Partners; and top contributors Mark Dale, XTec, Inc.; Gerry Smith, ID Technology Partners; and Rob Zivney, ID Technology Partners
  • Identity Council. Chair Tom Lockwood, NextgenID, Inc.; and top contributors David Kelts, GET Group North America; Geoff Slagle, AAMVA; Mike McCaskill, Florida Highway Patrol; Ted Sobel, Department of Homeland Security; Colin Wallis, Kantara Initiative; and Christopher Williams, Exponent, Inc.
  • Payments Council. Chair Jack Jania, CPI Card Group; Chair Oliver Manahan, Infineon Technologies; and top contributors Jose Correa, NXP Semiconductors; Francine Dubois, IDEMIA; Jordan Kaplan, Underwriters Laboratories (UL); and Nick Pisarev, G+D Mobile Security
  • Transportation Council. Chair Jerry Kane, Southeastern Pennsylvania Transportation Authority (SEPTA); and top contributor Brian Stein, Intueor

Council projects in 2020 included: white papers on mobile driver’s licenses (mDL), temporary identity credentials for federal employees, mobile devices and access control, biometric payment cards, dynamic security code cards, electric vehicle charging payments, contactless wearables, and Mobility as a Service (MaaS); industry comments on proposed government standards and specifications; and webinars/workshops on mDLs, biometric payment cards and electric vehicle charging payments.

For more information on Secure Technology Alliance Industry Councils, and the complete listing of the names and member organizations who qualified for the Council Honor Roll for 2020, visit https://www.securetechalliance.org/alliance-industry-councils/.

About the Secure Technology Alliance

The Secure Technology Alliance is the digital security industry’s premier association. The Alliance brings together leading providers and adopters of end-to-end security solutions designed to protect privacy and digital assets in payments, mobile, identity and access, healthcare, transportation and the emerging Internet of Things (IoT) markets.

The Alliance’s mission is to stimulate understanding, adoption and widespread application of connected digital solutions based on secure chip and other technologies and systems needed to protect data, enable secure authentication and facilitate commerce.

The Alliance is driven by its U.S.-focused member companies. They collaborate by sharing expertise and industry best practices through industry and technology councils, focused events, educational resources, industry outreach, advocacy, training and certification programs. Through participation in the breadth of Alliance activities, members strengthen personal and organizational networks and take away the insights to build the business strategies needed to commercialize secure products and services in this dynamic environment.

For more information, please visit www.securetechalliance.org.

CONTACT:

Adrian Loth and Dana Kringel
Montner Tech PR
203-226-9290
[email protected]
[email protected]



Amfil Technologies Inc. (OTC: FUNN) Announces New CEO

Toronto, ON, Nov. 25, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Amfil Technologies Inc. (OTC: FUNN) has hired Rogen K. Chhabra as its new CEO.  Rogen’s background is primarily in law and running successful businesses.  His business acumen is just what the company needs right now to get to the next level.

Rogen’s primary responsibility will be to oversee the Snakes & Lattes Inc. subsidiary, however he will also have oversight responsibility for all aspects of the company as we prepare for what is to come.  This will allow Ben Castanie to focus on the restaurant operations, which has proven to be a great use of his talents, and it will allow Roger Mortimer to maximize his best attributes working on the outdoor and cannabis sectors.

Major goals for Rogen are to:

  • Communicate with existing and prospective shareholders
  • Growth with focus on efficiency and maximizing revenue
  • Validating and streamlining company finances

To achieve these goals, Rogen has been tasked to get things done that have been proven difficult so far.  These include but are not limited to getting current on reporting, getting audits up to date, uplisting, and spin off of Interloc Kings Inc., Gro3 and other subsidiary sectors that are not a part of the Snakes & Lattes Inc. brand.

Rogen had been announced earlier this year as head of the USA expansion team.  He made significant progress in a short period of time before COVID necessarily required a pause.  But that did not stop Rogen from assisting the company in the background in a variety of ways.  Those within the company were impressed with Rogen’s seeming endless ability to get things done, even when he was not getting anything in return.

Management welcomes Rogen aboard, and we look forward to his leadership to take us to the next level.

Stay tuned for more updates coming soon.

About Snakes & Lattes

For further updates from the Snakes & Lattes and its parent company, Amfil Technologies Inc please follow us on Twitter @AmfilTech

For more information regarding the company, and its related subsidiaries please visit the following websites:

Amfil Technologies Inc. www.amfiltech.com

Snakes & Lattes Inc. www.snakesandlattes.com

Morning (Snakes & Lattes Publishing SAS) https://www.morning.us

GRO3 Joint Venture http://gro3systems.com

Interloc-Kings Inc. http://www.interloc-kings.com

About Us:

Amfil Technologies Inc. is the parent company to three wholly owned subsidiaries.

1). Snakes & Lagers Inc. holds the trade name and is the owner of Snakes & Lattes Inc. which currently operates 3 tabletop gaming bars and cafes located in Toronto, Ontario and 1 in Tempe, Arizona. The company is in the process of expanding throughout North America. Snakes & Lattes Inc. was the first board game bar and cafe in North America, is believed to be the largest in the world and has the largest circulating public library of board games in North America for customers to choose from. Snakes & Lattes Inc. currently has a 100+ member staff and recently acquired the exclusive distribution rights throughout Canada for some of the most popular board games in the world. The company also operates a lucrative fulfillment and distribution division and has recently entered into the board game publishing business through the acquisition of Morning which is expected to add significant revenues to the bottom line. For more information on Snakes & Lattes Inc. feel free to visit the website at www.snakesandlattes.com

2). The EcoPr03 GRO3 Antimicrobial System was jointly developed between Amfil Tech and A.C.T.S. Inc. which recently rebranded its technology under Advanced Ozone Integration as an extension of the existing ozone technology being utilized in the food and beverage industry and integrated by A.C.T.S. into companies such as Pepsi, Nestle, Sysco, Sun Pacific and many others. The system is a triple-function sanitization unit capable of naturally eliminating 99.9% of water and airborne pathogens and the typically problematic pests that wreak havoc for cultivators (like aphids, whiteflies and spider mites), as well as bacteria, fungus, microbes and mold on surfaces, all without chemicals. The unit can also constantly regulate a given facility’s water supply, oxygenating the water and maintaining a consistent PPM infusion of ozone that prevents the formation of algae, bacteria or mold (allowing for comprehensive water recycling), simultaneously removing the need to use pesticides and/or dangerous, often carcinogenic products to treat production problems, as is common throughout the industry today. This environmentally-friendly solution also eliminates odors, while slightly reducing the air temperature, lowering energy consumption by the HEPA filtration and HVAC systems and could potentially allow for a facilities process to be labeled certified organic in the U.S.A. when the crop is no longer considered illegal on the federal level, otherwise “Clean Green” or “Certified Kind” in the meantime. The EcoPr03 GRO3 Antimicrobial System recently passed product review by a registered USDA certifying agent for use in California as well as Pennsylvania and surrounding states. The subsidiary has developed a strategic partnership with Roto Gro, the creator of proprietary rotary hydroponic technology. More information on this product line can be found at www.gro3systems.com 

3). Interloc-Kings Inc. is a hardscape construction company servicing the Greater Toronto Area. This subsidiary is an authorized Unilock installer. Unilock is North America’s premier manufacturer of concrete interlocking paving stones and segmental wall products. Interloc-Kings Inc. has an A+ Rating with the Better Business Bureau (BBB) and a 10/10 rating on homestars.com. Specializing in stone and wood installations between $5,000 and $150,000 per project, Interloc-Kings Inc. has quickly become a top, high quality installation company of outdoor living areas in the GTA. More information on this subsidiary can be found at the website www.interloc-kings.com

Safe Harbor Statement

This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company’s OTC Market or Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as “may,” “should,”, “will”, “expect,” “anticipate,” “believe,” “estimate,” “confident,” “intend,” “plan” and other similar expressions. Our actual results, such as the Company’s ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Contact:

Roger Mortimer

Amfil Technologies Inc.

Telephone: (647) 880-5887

Email: [email protected]

Or

Ben Castanie

Snakes & Lattes Inc.

Telephone: (416) 500 2911

Email: [email protected]



Crooked Hammock Brewery Set to Open North Myrtle Beach Location February 2021

North Myrtle Beach, S.C., Nov. 25, 2020 (GLOBE NEWSWIRE) — Crooked Hammock Brewery is proud to announce plans to open its much-anticipated North Myrtle Beach location in February of 2021.

Crooked Hammock Brewery will bring an all-ages backyard escape experience to its campus at Barefoot Landing, which will include indoor/outdoor seating for more than 500 guests between the restaurant, craft brewery, Island Bar gazebo, and backyard beer garden with the Happy Camper food and beer truck, fire pits, hammocks, bocce ball courts, corn hole and a playground for kids.

“We are excited to bring Crooked Hammock Brewery to Barefoot Landing in North Myrtle Beach. This location showcases our easy drinking craft beers freshly brewed on site with tastings and brewery tours. We will soon announce our Myrtle Beach inspired brew and can’t wait to share it with our South Carolina friends,” said Owner Rich Garrahan.

The brewery will produce over 4,000 barrels in the first year, using 10 fermenters, 2 brite tanks and a 2-vessel 30BBL brewhouse. A tasting room will let beer lovers sample signature brews like Beach Escape, a session IPA bursting with citrus and hoppy goodness, South to Somewhere, a golden ale hopped and brewed with fresh coconut for a subtle tropical flavor, and other seasonal offerings. Tours of the brewery facilities will also be available.

The restaurant’s menu features outdoor cookout-inspired food like backyard burgers, oak-smoked baby back ribs, giant Bavarian pretzels, slow cooked coconut breaded wings with pineapple sauce and savory sides such as jalapeno cornbread with honey butter.

“We opened the Backyard Beer Garden Experience in July. We have enjoyed connecting with the local community and making friends of all ages while they spent the summer playing games, hanging out with the furry friends and enjoying a cold brew with us. We are currently hiring for all positions and look forward to welcoming new members to our team,” said William Morris, General Manager of Crooked Hammock North Myrtle Beach.

Crooked Hammock Brewery will employ up to 100 team members between full and part time positions and is currently hiring for all positions including brewery, front of house operations, kitchen and retail.  

A series of job fairs are scheduled. The first is on Monday, Nov. 30that thepre-opening office from 10:30AM-1:00PM and 3:30PM-6:00PM. The second is December 15th. For more information and to apply online, which is required before attending the job fair, visit crookedhammockbrewery.com/north-myrtle-job-fairs.

Interested parties can also complete an application online at any time, or come by the pre-opening office from 11 a.m. – 3 p.m., Monday through Friday, to discuss job opportunities with a CHB team member.

Crooked Hammock Brewery is part of La Vida Hospitality, a hospitality and entertainment company.

 

About Crooked Hammock Brewery

Crooked Hammock Brewery opened its doors for its first location in Lewes, Delaware in October of 2015. After four short years, it extended its reach just north of the original location with a 4,000 square foot space opening in Middletown, Delaware in fall 2019. Crooked Hammock is a craft brewery, restaurant and backyard beer garden that creates an easy-going, approachable environment. The craft beer lineup boasts light and perfectly crushable beers to lie in a hammock with and pairs nicely with the classic backyard cookout inspired menus. Its mission is to provide a place for all ages, incomes, and interests to experience and enjoy the hammock state of mind. Both locations include a backyard beer garden with activities for all ages, with hammocks, corn hole, ping-pong, playgrounds, bocce, and more.

About La Vida Hospitality

La Vida Hospitality is a hospitality and entertainment management company based out of Rehoboth Beach, Delaware. La Vida is a leader in creating lifestyle-focused hospitality brands that create emotional bonds with its team, guests and surrounding communities. The brands it develops embrace the mentality of taking a break, enjoying the ride, and always making memories along the way. More information about La Vida Hospitality can be found online at www.lavidahospitality.com.

Attachments



Gina Vasselli
LHWH Advertising and Public Relations
843-448-1123
[email protected]

Third Quarter 2020 Financial Results

Safe-T Announces Record Revenue of $3,591,000 for the First Nine Months of 2020,
Presenting Growth of 65% Compared to the Equivalent Period in 2019

HERZLIYA, Israel, Nov. 25, 2020 (GLOBE NEWSWIRE) — Safe-T® Group Ltd. (Nasdaq, TASE: SFET), a provider of secure access solutions for on-premise and hybrid cloud environments, today announced its financial results for the nine and three month periods ended September 30, 2020.

Revenues for the first nine months of 2020 totaled $3,591,000, an increase of 65% compared to $2,170,000 in the first nine months of 2019. Revenues for the three-month period ended September 30, 2020 reached a record high and totaled $1,426,000, an increase of 6% compared to $1,349,000 in the three-month period ended September 30, 2019.

The Company’s cash balance at the end of the quarter was $13,841,000.

Shachar Daniel, Chief Executive Officer, commented on the results: “The last quarter was a very successful one for us. We continued to receive great feedback from the Zero Trust market for the uniqueness, the potential, and the growing need for our Zone Zero solutions. Over the last quarter we have continued to strive towards achieving our goals: (i) accelerating market awareness; (ii) reaching the next stage with our global partners network and further educating them about our products while supporting them with the initial end-customers’ implementations; and (iii) expanding our market opportunity with our IP proxy products, by developing a set of capabilities that will allow us to lead the market. In addition, we are going forward and examining potential M&A targets that could strengthen our capabilities and offerings to the markets in which we operate.”

Mr. Daniel concluded” “This quarter was characterized by extensive progress in all major areas, including towards achieving major milestones for scaling up revenues in the upcoming quarters. Over the period we learned that Remote Access is here to stay, and we have the right technology to disrupt this market.”


Third Quarter and Recent Business Developments:
 

  • On November 6, 2020, Safe-T presented a breakthrough in the new version of its Zero Trust Remote Access Solution. The Company achieved a significant milestone with its Zero Trust ZoneZero™ solution having now been deployed by multiple Asian leading channels ready to market it to their customers.
  • Significant expansion in the Company’s global partners network, including agreements with leading international and regional resellers such as Softprom Distribution GmbH (Central and Eastern Europe, CIS countries), HTC Global Services (India and U.S.) and iValue InfoSolutions PVT (India).
  • On August 24, 2020, NetNut Ltd., a wholly-owned subsidiary of the Company, has launched its Dynamic Residential Proxy network in Europe and Asia.
  • On July 22, 2020, the Company completed a registered direct offering of ADSs and pre-funded warrants with gross proceeds of approximately $5,907,000.
  • Between July 1, 2020 and August 28, 2020, 739,000 warrants from the Company’s April 23, 2020 underwritten public offering were exercised, for an aggregate of $887,000, in addition to the exercise of 435,000 pre-funded warrants from the Company’s July 2020 registered direct offering.


Financial Results for the Nine Months Ended September 30, 2020:

  • Total revenues amounted to $3,591,000 (First nine months of 2019: $2,170,000). The increase in revenues is due to the consolidation of revenues generated by NetNut throughout the entire period compared to the consolidation in 2019 which occurred only from NetNut’s acquisition on June 12, 2019 until the period ended September 30, 2019. The increase was partially offset by a reduction in sales of the Secure Data Exchange (SDE) product, as part of the Company’s strategic plan to focus on the Software Defined Perimeter (SDP) market with its Zero-Trust solutions.
  • Cost of revenues totaled $1,688,000 (First nine months of 2019: $1,020,000). The increase is mainly due to the consolidation of NetNut’s cost of revenues, as well as amortization of NetNut’s intangible assets, partially offset by a decrease of costs resulting from the streamlining of support and post sales teams in the cyber business.
  • Research and development (R&D) expenses totaled $1,448,000 (First nine months of 2019: $1,936,000). The decrease is due to a significant reduction in the SDE solution development costs, partially offset by the consolidation of NetNut’s development costs and subcontractors’ costs related to the new Zero Trust solutions.
  • Sales and marketing expenses totaled $2,895,000 (First nine months of 2019: $2,687,000). The increase is primarily attributed to consolidation of NetNut’s sales and marketing costs, partially offset by efficiency measures and cost reductions in overall sales, professional and marketing costs of the cyber business.
  • General and administrative expenses (G&A) totaled $2,908,000 (First nine months of 2019: $2,457,000). The increase is mainly due to the consolidation of NetNut’s general and administrative costs, and an increase in professional fees costs and salaries, partially offset by a reduction in share-based payments.
  • IFRS net loss totaled $2,836,000, or $0.01 basic loss per ordinary share (First nine months of 2019: loss of $1,706,000, or $0.22 basic loss per ordinary share).
  • Non-IFRS net loss was $3,948,000, or $0.01 basic loss per ordinary share (First nine months of 2019: loss of $5,056,000, or $0.66 basic loss per ordinary share).


Financial Results for the Three Months Ended September 30, 2020:

  • Total revenues amounted to $1,426,000 (Q3 2019: $1,349,000). The increase is mainly attributed to a sale of a Zero Trust solution to a leading intelligence unit, partially offset by a decrease in the revenues of the SDE product.
  • Cost of revenues totaled $567,000 (Q3 2019: $604,000). The decrease is mainly due to lack of further amortization of the SDE intangible assets, partially offset by a small increase of salary costs.
  • R&D expenses totaled $655,000 (Q3 2019: $563,000). The increase is mainly attributed to an increase of NetNut’s development costs due to an extension of its proxy solutions activity, subcontractors’ costs related to the new Zero Trust solutions and share-based compensation, partially offset by the cease of development efforts related to the SDE product.
  • Sales and marketing expenses totaled $1,114,000 (Q3 2019: $1,050,000). The increase is primarily attributed to professional services related to the marketing and sales of the new Zero Trust solutions and share-based compensation, partially offset by decrease in salary costs of the cyber business direct sales force due to the reduced efforts to sell the SDE product.
  • G&A expenses totaled $1,413,000 (Q3 2019: $828,000). The increase is mainly in professional fees costs, salaries, and share-based compensation.
  • IFRS net loss totaled $1,292,000, or $0.00 basic loss per ordinary share (Q3 2019: net profit of $804,000, or $0.07 basic earnings per ordinary share).
  • Non-IFRS net loss totaled $1,713,000, or $0.00 basic loss per ordinary share (Q3 2019: loss of $1,531,000, or $0.13 basic loss per ordinary share).

All descriptions of Safe-T’s share capital in this press release, including share amounts and per share amounts, are presented after giving effect to the reverse split that the Company effected on October 21, 2019.

The following table presents the reconciled effect of the non-cash expenses/income and certain expenses further described below on the Company’s net loss (profit) for the nine and three month periods ended September 30, 2020 and 2019, and for the year ended December 31, 2019:

    For the Nine-Month

Period Ended

September 30,
    For the Three-Month

Period Ended

September 30,
    For the year Ended

December 31,
 
(thousands of U.S. dollars)   2020     2019     2020     2019     2019  
                               
Net loss (profit) for the period     2,836       1,706       1,292       (804 )     12,998  
Issuance and acquisition costs     156                         790  
Amortization and impairment of intangible assets and goodwill     1,636       543       330       342       2,105  
Share-based compensation     349       533       309       3       454  
Finance liabilities at fair value     (3,253 )     (4,426 )     (985 )     (2,680 )     2,596  
Total adjustment     (1,112 )     (3,350 )     (346 )     (2,335 )     5,945  
Non-IFRS net loss     3,948       5,056       1,638       1,531       7,053  


Balance Sheet Highlights:

  • As of September 30, 2020, shareholders’ equity totaled $20,841,000, or approximately $1.19 per outstanding ADS as of September 30, 2020, compared to shareholders’ equity of $2,777,000 on December 31, 2019. The increase is due mainly to equity raised through the issuance of ADSs and pre-funded warrants and warrant exercises as well as debenture conversions, partially offset by the Company’s operating loss during the first nine months of 2020.
  • As of September 30, 2020, the Company’s cash balance was $13,841,000.


COVID-19 Impacts

Beginning in March 2020, Israel, where our headquarters office is located, began enforcing social distancing and other rules to limit the spread of infection of COVID-19, which forced us to modify our business practices. We adopted early and strict prevention measures to protect the health of our employees (including employees’ travel, employees’ work locations and cancellation of physical participation in meetings, events and conferences). In September 2020, the Israeli government announced a second lockdown plan, the restrictions of which are being gradually eased since the end of October 2020. Thanks to the resilience of our operational capabilities, we have been able to continuously serve our clients during this crisis as we leveraged our IT expertise to implement remote connections with employees, customers and vendors, to deliver a functional and productive work-from-home strategy.

As there remains a great deal of uncertainty surrounding the trends and duration of the impact of the COVID-19 pandemic on the Company, we remain focused on maintaining our financial flexibility and continue to manage our cash flow and capital allocation decisions to navigate through this challenging environment. Based on the operating, financial and business strategies the Company has implemented, the Company strongly believes that it has sufficient resources that will enable us to successfully adapt as the situation evolves.

Use of Non-IFRS Financial Results

In addition to disclosing financial results calculated in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board, this press release contains non-IFRS financial measures of net loss for the periods presented that exclude the effect of share-based compensation expenses, amortization of intangible assets, non-cash issuance and acquisition expenses and the revaluation of finance liabilities at fair value. The Company’s management believes the non-IFRS financial information provided in this release is useful to investors’ understanding and assessment of the Company’s ongoing operations. Management also uses both IFRS and non-IFRS information in evaluating and operating its business internally, and as such deemed it important to provide this information to investors. The non-IFRS financial measures disclosed by the Company should not be considered in isolation, or as a substitute for, or superior to, financial measures calculated in accordance with IFRS, and the financial results calculated in accordance with IFRS and reconciliations to those financial statements should be carefully evaluated. Investors are encouraged to review the reconciliations of these non-IFRS measures to their most directly comparable IFRS financial measures provided in the financial statement tables herein. 

About Safe-T® Group Ltd.

Safe-T Group Ltd. (Nasdaq, TASE: SFET) is a provider of Zero-Trust Access solutions which mitigate attacks on enterprises’ business-critical services and sensitive data, while ensuring uninterrupted business continuity. Safe-T’s cloud and on-premises solutions ensure that an organization’s access use cases, whether into the organization or from the organization out to the internet, are secured according to the “validate first, access later” philosophy of Zero Trust. This means that no one is trusted by default from inside or outside the network, and verification is required from everyone trying to gain access to resources on the network or in the cloud.

Safe-T’s wide range of access solutions reduce organizations’ attack surface and improve their ability to defend against modern cyberthreats. As an additional layer of security, our integrated business-grade global proxy solution cloud service enables smooth and efficient traffic flow, interruption-free service, unlimited concurrent connections, instant scaling and simple integration with our services.

With Safe-T’s patented reverse-access technology and proprietary routing technology, organizations of all size and type can secure their data, services and networks against internal and external threats.

Safe-T’s SDP solution on AWS Marketplace is available here

For more information about Safe-T, visit www.safe-t.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Safe-T is using forward-looking statements in this press release when it discusses its outlook for the future, achieving its goals, including: accelerating market awareness, reaching the next stage with global partners network and expanding market opportunity with IP proxy products, and when it discusses examining potential M&A targets that could strengthen the Company’s capabilities and offerings, that Remote Access is here to stay, and the impact of COVID-19. Because such statements deal with future events and are based on Safe-T’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Safe-T could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Safe-T’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 31, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Safe-T undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Safe-T is not responsible for the contents of third-party websites.

Contact Investor Relations

Michal Efraty
+972-(0)52-3044404
[email protected] 

Consolidated Statements of Financial Position

(In thousands of USD)

    September 30,     December 31,  
    2020     2019     2019  
    (Unaudited)     (Audited)  
Assets                  
Current assets:                  
Cash and cash equivalents     13,841       973       4,341  
Restricted deposits           110       29  
Trade receivables     676       678       680  
Other receivables     839       679       470  
Total current assets     15,356       2,440       5,520  
                         
Non-current assets:                        
Long-term restricted deposits     83             82  
Long-term deposit     50             44  
Property, plant and equipment, net     169       296       266  
Right of use assets     419       455       441  
Goodwill     6,077       7,879       6,877  
Intangible assets, net     3,845       5,193       4,607  
Total non-current assets     10,643       13,823       12,317  
Total assets     25,999       16,263       17,837  
                         
Liabilities and equity                        
Current liabilities:                        
Short-term loan           14       4  
Trade payables     179       441       237  
Other payables     1,162       1,509       1,553  
Contract liabilities     325       548       562  
Contingent consideration     1,000       2,234       2,170  
Convertible debentures                 7,151  
Derivative financial instruments     994             1,637  
Short-term lease liabilities     196       191       184  
Liability in respect of the Israeli Innovation Authority           27       8  
Total current liabilities     3,856       4,964       13,506  
                         
Non-current liabilities:                        
Contract liabilities     39       125       82  
Long-term lease liabilities     276       340       324  
Deferred tax liabilities     856       992       1,040  
Derivative financial instruments                  
Convertible debentures           1,699        
Liability in respect of the Israeli Innovation Authority     131       101       108  
Total non-current liabilities     1,302       3,257       1,554  
Total liabilities     5,158       8,221       15,060  
                         
Equity:                        
Ordinary shares                  
Share premium     70,574       47,424       52,394  
Other equity reserves     15,790       12,013       13,070  
Accumulated deficit     (65,523 )     (51,395 )     (62,687 )
Total equity     20,841       8,042       2,777  
Total liabilities and equity     25,999       16,263       17,837  

Consolidated Statements of Profit or Loss

(In thousands of USD, except per share amounts)

    For the Nine Months Ended

September 30,
    For the Three Months Ended

September 30,
    For the Year Ended December 31,  
    2020     2019     2020     2019     2019  
    (Unaudited)     (Unaudited)     (Unaudited)     (Unaudited)     (Audited)  
                               
Revenues     3,591       2,170       1,426       1,349       3,284  
Cost of revenues     1,688       1,020       567       604       1,889  
Gross profit     1,903       1,150       859       745       1,395  
                                         
Research and development expenses     1,448       1,936       655       563       2,485  
Sales and marketing expenses     2,895       2,687       1,114       1,050       3,783  
General and administrative expenses     2,908       2,457       1,413       828       3,757  
Impairment of goodwill     800                         1,002  
Contingent consideration measurement     430       223             223       159  
Operating expenses     (8,481 )     (7,303 )     (3,182 )     (2,664 )     (11,186 )
                                         
Operating loss     (6,578 )     (6,153 )     (2,323 )     (1,919 )     (9,791 )
                                         
Finance income (expenses), net     3,558       4,415       969       2,694       (3,184 )
Tax benefit (taxes on income)     184       32       62       29       (23 )
Net income (loss)     (2,836 )     (1,706 )     (1,292 )     804       (12,998 )
                                         
Basic loss (profit) per share*     (0.01 )     (0.22 )     (0.00 )     0.07       (0.96 )
                                         
Diluted loss per share*     (0.02 )     (0.42 )     (0.00 )     (0.08 )     (1.03 )

  * Adjusted retrospectively to reflect a 20:1 reverse share split of our ordinary shares effective as October 21, 2019



Equillium Provides Itolizumab COVID-19 Program Update

Analyst Day scheduled for December 4, 2020

LA JOLLA, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that due to the rapidly evolving COVID-19 treatment landscape, the company will not initiate the EQUINOX Phase 3 clinical trial to evaluate itolizumab in hospitalized COVID-19 patients at this time.

“Based on a thorough review of recent updates regarding the efficacy of new potential vaccines and other treatment options, we have made the strategic decision not to initiate our EQUINOX Phase 3 trial as previously planned. We are continuing to assess the rapidly evolving clinical and commercial landscape related to this pandemic and may consider other options to evaluate itolizumab in COVID-19 patients, including government research initiatives,” said Bruce Steel, chief executive officer of Equillium. “While this is a difficult decision given the current high rates of infection and significant unmet medical need, we believe it is prudent given the recent positive advancements by our biopharma colleagues to combat this serious pandemic. We greatly appreciate the support and effort of our trial investigators, clinical trial sites, and our Equillium team who played a vital role in preparing for the EQUINOX study, especially during this challenging time.”

Mr. Steel added, “Based on recent positive itolizumab interim clinical data in acute graft-versus-host disease (aGVHD) we plan to prioritize our resources on expanding and accelerating this program, as well as advancing our lupus / lupus nephritis and uncontrolled asthma studies. We look forward to providing additional pipeline updates at our Analyst Day on Friday, December 4.”

About Itolizumab

Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is currently being evaluated in multiple clinical trials in patients with severe diseases, including aGVHD, lupus / lupus nephritis and uncontrolled asthma. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Itolizumab is marketed in India under the trade name “ALZUMAb-L” for the treatment of chronic plaque psoriasis and has received emergency use approval in India to treat cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including, aGVHD, lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential benefit of treating patients with aGVHD, uncontrolled asthma, lupus / lupus nephritis, or COVID-19 with itolizumab, Equillium’s business strategy, Equillium’s plans and expected timing for developing itolizumab, including the expected timing of initiating, completing and announcing further results from the EQUATE, EQUIP and EQUALISE studies, the potential benefits of itolizumab, the potential for the any of Equillium’s ongoing or planned clinical trials to show safety or efficacy, the impact of the COVID-19 pandemic. Risks that contribute to the uncertain nature of the forward-looking statements include: the risk that interim results of a clinical trial do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the risk that studies will not be completed as planned; uncertainties related to Equillium’s capital requirements; Equillium’s plans and product development, including the initiation, restarting and completion of clinical trials; uncertainties related to the actual impacts and length of such impacts caused by the COVID-19 pandemic; uncertainties caused by the recent restarting of the EQUIP and EQUALISE clinical trials after a pause; whether the results from clinical trials will validate and support the safety and efficacy of itolizumab; changes in the competitive landscape, and uncertainties having to use cash in ways or on timing other than expected and the impact of market volatility on cash reserves. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in Equillium’s filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact

Michael Moore,
Vice President, Investor Relations & Corporate Communications
+1-619-302-4431
[email protected]

Media Contact

Katherine Carlyle Smith
Senior Account Associate
Canale Communications
+1-805-907-2497
[email protected]



iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress

Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types

NASHUA, N.H., Nov. 25, 2020 (GLOBE NEWSWIRE) —  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that researchers from Miguel Servet University Hospital in Zaragoza, Spain, will present new data from three clinical studies supporting the efficacy of the expanded Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast and endometrial cancers during the European Society for Radiotherapy & Oncology (ESTRO) 2020 meeting held virtually November 28 through December 1.

The Company will highlight the latest technology for the expanded Xoft platform, including its full suite of applicators for existing and emerging applications in the virtual Xoft booth.

“We’re thrilled to have new clinical evidence presented at ESTRO 2020 to further demonstrate the value of the Xoft System for the treatment of early-stage breast and gynecological cancers,” said Michael Klein, Chairman and CEO of iCAD. “In particular, we are encouraged by the results indicating that our GYN eBx application is a feasible alternative to high dose rate (HDR) brachytherapy with radioactive Iridium 192, providing the same clinical benefits, yet with a marked reduction in radiation exposure to nearby organs at risk.

“Two other posters evaluating Xoft IORT pave the way for future research to fine-tune individual patient treatment plans,” continued Klein. “These data complement our growing body of research supporting Xoft’s advanced, multi-platform system for the efficient and targeted treatment of multiple cancer types.”

Clinicians from Hospital Universitario Miguel Servet first adopted the technology in 2015. Since that time, they have treated more than 600 early-stage breast cancer patients and 150 gynecological cancer patients with the Xoft IORT System. Information and a summary of the research being presented during the ESTRO 2020 Program are listed below:


  • PO-1144

    : “Adjuvant
    E
    lectronic
    B
    rachytherapy for
    P
    atients with
    E
    ndometrial
    C
    ancer
    ,
    presented by María Cerrolaza, MD, Miguel Servet University Hospital. This study analyzed 193 patients from 2015 to 2019, where one group was treated with Xoft eBx combined with external radiation and one group was treated with Xoft eBx. Researchers established that electronic brachytherapy for endometrial cancer as a feasible alternative to HDR brachytherapy, equal in effectiveness to Iridium 192, with long-term benefits for patients., Xoft eBx provided the same dosimetric coverage in the area of treatment as traditional brachytherapy with a marked reduction in dosage to organs at risk.


  • PO-1319

    :
    “Design of a
    P
    hantom for
    Verification
    of IORT
    T
    reatments and
    I
    n
    V
    ivo
    D
    osimetry
    S
    imulation,” presented by Sergio Lozares, MD, Miguel Servet University Hospital. Researchers created 3D printed phantoms that allowed them to create simulations to measure possible radiation doses in nearby organs, such as the lung and heart, where it is not possible to place a detector to perform in vivo dosimetry. Results calculated the maximum doses to radiochromic film representing the left lung and heart of 20 patients treated from the left breast measured retrospectively. Researchers concluded it was possible to measure and verify doses in the lung and heart for IORT treatments, enabling more accurate recommendations for a particular type of treatment.


  • PO 1350

    : “In Vivo Dosimetry with XR-RV3 Radiochromic Films in Intraoperative Radiotherapy of the Breast,” presented by Sergio Lozares, MD, Miguel Servet University Hospital. The study examined the results of 480 patients treated with IORT from May 2015 – October 2019 with treatment verification and in vivo dose measurements to understand the in vivo dose in the skin. Researchers concluded the skin doses were low with less than 1% of the cases exhibiting early toxicity of acute grade 3 dermatitis and no cases of higher grade.

“Traditionally, HDR intracavitary brachytherapy using Iridium 192 seeds has been used for patients with endometrial cancer, but the recent development of electronic brachytherapy based on a miniaturized X-ray source has important advantages over HDR,” said Martin Tejedor, MD PhD, Chairman of Aragon Radiation Oncology Multihospital Clinical Unit (UCMORA). “The ability to precisely target cancer cells while preserving surrounding healthy tissue has significantly improved patient outcomes. Our study found long-term advantages with Xoft eBx, providing the same benefits as traditional methods with a reduction in radiation toxicity to at-risk organs.”

The Xoft system is FDA-cleared and CE-marked for the treatment of cancer anywhere in the body including early stage breast cancer, gynecological cancers and non-melanoma skin cancer. Emerging applications include prostate, colorectal and brain cancers. Treatment with Xoft IORT is accelerating treatment times and minimizing COVID-19 exposure to patients and clinicians.

Last month, new research supporting the Xoft System for the treatment of recurrent glioblastoma (GBM) was presented at the European Association of Neurosurgical Societies (EANS) Virtual Congress by Alexey Gaytan, MD, PhD, a neurosurgeon at the European Medical Center (EMC) in Moscow, Russia. The latest results demonstrate significant improvement in overall survival (OS) and local progression-free survival (locPFS) in patients with recurrent GBM treated with Xoft Intraoperative Radiotherapy (IORT) versus patients treated with external beam radiation therapy (EBRT) and systemic therapy.

The study, under the guidance of Lead Investigator, Alexey Krivoshapkin, MD, PhD, a neurosurgeon at the EMC, involves 28 patients with recurrent GBM who were treated between August 2016 and June 2019. All patients underwent maximal safe resection. Researchers concluded that IORT of recurrent GBM is feasible and provides encouraging local progression-free and overall survival, with a manageable toxicity profile, and that further clinical trials are warranted.

As of May 2020, 5 patients from the IORT group were still alive, whereas none of the patients in the EBRT group survived. Our earlier release of January survival data included 7 patients surviving as of mid-December 2019. The survival of patients in the IORT group ranged from 16 – 59 months after the initial GBM diagnosis. As previously disclosed, the EBRT group survival ranged from 5.5 – 38.5 months after initial GBM diagnosis.

iCAD recently assembled a panel of experts to expand research on Xoft Brain IORT to multiple leading cancer centers worldwide. The Company is also exploring other emerging applications for the Xoft System, including the treatment of early-stage rectal tumors.

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

The Xoft System is a 50 kV radiation oncology treatment solution that uses a miniaturized X-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site while minimizing risk of damage to healthy tissue in nearby areas of the body. The isotope-free radiation requires minimal shielding, enabling medical professionals to remain in the room during treatment.

For more information, visit www.icadmed.com and www.xoftinc.com.

Forward-Looking Statements

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the ability of IORT to provide flexibility, mobility or other advantages, to be more beneficial for patients than traditional therapy or to be accepted by patients or clinicians, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Media Inquiries:

Maria Stanieich, iCAD
+1 (603) 309-1949

Investor Relations:

Jeremy Feffer, LifeSci Advisors
+1 (212) 915-2568
[email protected] 



Motus GI Scheduled to Participate in the Piper Sandler 32nd Annual Healthcare Conference

FORT LAUDERDALE, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its management team is scheduled to participate in the Piper Sandler 32nd Annual Healthcare Conference, which is scheduled to take place virtually from December 1-3, 2020.

Tim Moran, Chief Executive Officer of Motus GI, will participate in a fireside chat that will be available via webcast on the Piper Sandler conference site (click here) from November 25th to December 3rd, and on the Events page on the Company’s website, www.motusgi.com. An archive of the webcast will continue to be available on the Company’s website for 90 days.

In addition, the Motus GI management team will be participating in 1×1 meetings on December 2, 2020, meetings may be requested exclusively via Piper Sandler.

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.


Investor Contact:


Bob Yedid
LifeSci Advisors
(646) 597-6989
[email protected]



Jounce Therapeutics to Participate in a Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president, and Elizabeth Trehu, M.D., chief medical officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.

A pre-recorded fireside chat will be available beginning on Tuesday, December 1, 2020 at 8:00 a.m. ET and can be viewed by visiting “Events & Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days.

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the SELECT trial and with Jounce’s broader pipeline. Jounce’s next development stage product candidate, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state. A Phase 1 trial evaluating JTX-8064 is planned to begin enrollment in the fourth quarter of 2020. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Investor
and Media
Contact
s
:

Malin Deon
Jounce Therapeutics, Inc.
+1-857-259-3843
[email protected]

Mark Yore
Jounce Therapeutics, Inc.
+1-857-200-1255
[email protected]



ENZO BIOCHEM ANNOUNCES APPOINTMENT OF IAN B. WALTERS, MD, TO ITS BOARD OF DIRECTORS

NEW YORK, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that Ian B. Walters, MD, has been appointed to the Company’s Board of Directors effective immediately.    

Dr. Walters is an experienced entrepreneur and drug developer with leadership in the development of over 30 drugs in multiple therapeutic areas involving diverse technologies, leading to five new oncology drug approvals. His previous positions include Executive Director of Global Oncology Clinical Research and Business Development for Bristol-Myers Squibb, and Medical Director at Millennium Pharmaceuticals. Dr. Walters currently is CEO and Director of Portage Biotech, a publicly traded clinical stage biopharmaceutical company developing an innovative portfolio of immuno-oncology assets. He is also founder of seven of Portage’s portfolio companies.

Dr. Walters holds an MBA from the Wharton School of the University of Pennsylvania. He received his MD at the Albert Einstein College of Medicine and completed doctoral training in experimental medicine at The Rockefeller University.  Dr. Walters has been the lead author or contributor to approximately 60 journal publications.

“Dr. Walters brings over two decades of diverse experience in drug development and business strategy, including both founding and executive level positions at several life sciences companies,” said Dr. Elazar Rabbani, Ph.D., Enzo’s Chairman and Chief Executive Officer.  “As a physician, scientist and entrepreneur, his deep expertise spans clinical development, regulatory affairs, and strategic planning.  At a time when we have announced promising growth and continued momentum going into 2021, Dr. Walters will play an integral role in identifying new ways Enzo’s offerings can effectively support companion diagnostics, early drug discovery, and liquid biopsy techniques.”

 “Enzo continues to demonstrate its role as an innovative leader through its rapid response to the COVID-19 pandemic and continued implementation of cost effective, adaptive technologies to address key challenges in the clinical diagnostics industry,” said Dr. Walters.  “I am eager to work together with the other members of the board and Enzo’s management team to assure its future success and target new opportunities for growth.”


About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies. For additional information please visit: http://www.enzo.com/


Forward-Looking Statements

Except for historical information, the matters discussed in this release may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2020. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.

###


Contacts:

David Bench, CFO
Enzo Biochem, Inc.
212-583-0100
[email protected]

Media:

Marisa Monte           
Berry & Company Public Relations
212-253-8881
[email protected]

Investors:

Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
[email protected]

Steve Anreder
Anreder & Company
212-532-3232
[email protected]